You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

AstraZeneca Pharma India to launch cancer drug

Capital Market 

The drug maker on Thursday said it will launch its Acalabrutinib 100 mg capsules, used for treatment of various types of blood cancers, under the brand name Calquence in India on 21 October.

The drug is indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It is also indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

Astrazeneca Pharma India's net profit fell 13.4% to Rs 18.63 crore on 5.4% decline in net sales to Rs 193.58 crore in Q1 June 2020 over Q1 June 2019.

Shares of Astrazeneca Pharma India were up 0.29% to Rs 4,279.15.

AstraZeneca Pharma India is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. As of 30 June 2020, UK-based AstraZeneca Pharma holds 75% stake in AstraZeneca Pharma India.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 16 2020. 09:24 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU